ALLO
Allogene Therapeutics, Inc.
ALLO
(1.2)1,87 USD
-43.05% ROA
-58.07% ROE
-1.87x PER
572.966.880,00 USD
18.29% DER
0% Yield
-659137.21% NPM
Allogene Therapeutics, Inc. Stock Analysis
Allogene Therapeutics, Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
PBV
With a remarkably low PBV ratio (0.85x), the stock offers substantial upside potential at a bargain price. |
|
| 2 |
DER
The stock has a low debt to equity ratio (15%), which means it has a small amount of debt compared to the ownership it holds |
|
| 3 |
Graham Number
The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity. |
|
| 4 |
ROE
The stock's ROE indicates a negative return (-53.72%) on shareholders' equity, suggesting poor financial performance. |
|
| 5 |
ROA
The stock's ROA (-46.46%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment. |
|
| 6 |
Revenue Growth
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option. |
|
| 7 |
Net Profit Growth
Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option. |
|
| 8 |
Assets Growth
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity. |
|
| 9 |
Dividend Growth
Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns. |
|
| 10 |
Dividend
The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns. |
|
| 11 |
Buffet Intrinsic Value
Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value. |
Allogene Therapeutics, Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Buy |
| 2 | MACD | Buy |
| 3 | RSI | Sell |
| 4 | Stoch RSI | Sell |
Allogene Therapeutics, Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2017 | 0 | |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 38.489.000 | 100% |
| 2022 | 243.000 | -15739.09% |
| 2023 | 172.000 | -41.28% |
| 2023 | 95.000 | -81.05% |
| 2024 | 0 | 0% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2017 | 0 | |
| 2018 | 151.860.000 | 100% |
| 2019 | 144.535.000 | -5.07% |
| 2020 | 192.987.000 | 25.11% |
| 2021 | 220.176.000 | 12.35% |
| 2022 | 256.387.000 | 14.12% |
| 2023 | 183.908.000 | -39.41% |
| 2023 | 242.914.000 | 24.29% |
| 2024 | 186.844.000 | -30.01% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2017 | 24.000 | |
| 2018 | 40.982.000 | 99.94% |
| 2019 | 57.473.000 | 28.69% |
| 2020 | 65.256.000 | 11.93% |
| 2021 | 74.105.000 | 11.94% |
| 2022 | 79.305.000 | 6.56% |
| 2023 | 68.164.000 | -16.34% |
| 2023 | 71.673.000 | 4.9% |
| 2024 | 64.348.000 | -11.38% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2017 | -2.000 | |
| 2018 | -208.264.000 | 100% |
| 2019 | -184.925.000 | -12.62% |
| 2020 | -258.243.000 | 28.39% |
| 2021 | -255.792.000 | -0.96% |
| 2022 | -335.449.000 | 23.75% |
| 2023 | -237.612.000 | -41.18% |
| 2023 | -287.048.000 | 17.22% |
| 2024 | -251.192.000 | -14.27% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2017 | 0 | |
| 2018 | -1.500.000 | 100% |
| 2019 | -5.027.000 | 70.16% |
| 2020 | -11.541.000 | 56.44% |
| 2021 | 25.424.000 | 145.39% |
| 2022 | -16.485.000 | 254.23% |
| 2023 | 172.000 | 9684.3% |
| 2023 | -242.819.000 | 100.07% |
| 2024 | -14.576.000 | -1565.88% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2017 | -2.000 | |
| 2018 | -211.505.000 | 100% |
| 2019 | -184.594.000 | -14.58% |
| 2020 | -233.471.000 | 20.93% |
| 2021 | -244.837.000 | 4.64% |
| 2022 | -329.815.000 | 25.77% |
| 2023 | -245.260.000 | -34.48% |
| 2023 | -327.265.000 | 25.06% |
| 2024 | -265.432.000 | -23.3% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2017 | 0 | |
| 2018 | -7 | 100% |
| 2019 | -2 | -600% |
| 2020 | -2 | 0% |
| 2021 | -2 | 0% |
| 2022 | -2 | 50% |
| 2023 | -1 | -100% |
| 2023 | -2 | 50% |
| 2024 | -1 | -100% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2017 | 0 | |
| 2018 | -47.887.000 | 100% |
| 2019 | -188.141.000 | 74.55% |
| 2020 | -181.051.000 | -3.92% |
| 2021 | -206.258.000 | 12.22% |
| 2022 | -225.710.000 | 8.62% |
| 2023 | -239.249.000 | 5.66% |
| 2023 | -55.542.000 | -330.75% |
| 2024 | -63.588.000 | 12.65% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2017 | 0 | |
| 2018 | -44.653.000 | 100% |
| 2019 | -137.350.000 | 67.49% |
| 2020 | -115.093.000 | -19.34% |
| 2021 | -184.812.000 | 37.72% |
| 2022 | -220.519.000 | 16.19% |
| 2023 | -237.733.000 | 7.24% |
| 2023 | -55.530.000 | -328.12% |
| 2024 | -63.588.000 | 12.67% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2017 | 0 | |
| 2018 | 3.234.000 | 100% |
| 2019 | 50.791.000 | 93.63% |
| 2020 | 65.958.000 | 22.99% |
| 2021 | 21.446.000 | -207.55% |
| 2022 | 5.191.000 | -313.14% |
| 2023 | 1.516.000 | -242.41% |
| 2023 | 12.000 | -12533.33% |
| 2024 | 0 | 0% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2017 | -2.000 | |
| 2018 | 703.164.000 | 100% |
| 2019 | 629.023.000 | -11.79% |
| 2020 | 1.079.617.000 | 41.74% |
| 2021 | 916.406.000 | -17.81% |
| 2022 | 665.870.000 | -37.63% |
| 2023 | 583.102.000 | -14.19% |
| 2023 | 512.233.000 | -13.84% |
| 2024 | 515.038.000 | 0.54% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2017 | 0 | |
| 2018 | 773.855.000 | 100% |
| 2019 | 717.802.000 | -7.81% |
| 2020 | 1.227.829.000 | 41.54% |
| 2021 | 1.038.634.000 | -18.22% |
| 2022 | 817.079.000 | -27.12% |
| 2023 | 712.326.000 | -14.71% |
| 2023 | 642.837.000 | -10.81% |
| 2024 | 646.883.000 | 0.63% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2017 | 2.000 | |
| 2018 | 70.691.000 | 100% |
| 2019 | 88.779.000 | 20.37% |
| 2020 | 148.212.000 | 40.1% |
| 2021 | 122.228.000 | -21.26% |
| 2022 | 151.209.000 | 19.17% |
| 2023 | 129.224.000 | -17.01% |
| 2023 | 130.604.000 | 1.06% |
| 2024 | 131.845.000 | 0.94% |
Allogene Therapeutics, Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 0
- Net Income per Share
- -1.47
- Price to Earning Ratio
- -1.87x
- Price To Sales Ratio
- 6662.41x
- POCF Ratio
- -2.28
- PFCF Ratio
- -2.5
- Price to Book Ratio
- 1.01
- EV to Sales
- 5773.37
- EV Over EBITDA
- -1.93
- EV to Operating CashFlow
- -2.17
- EV to FreeCashFlow
- -2.17
- Earnings Yield
- -0.53
- FreeCashFlow Yield
- -0.4
- Market Cap
- 0,57 Bil.
- Enterprise Value
- 0,50 Bil.
- Graham Number
- 9.45
- Graham NetNet
- 1.65
Income Statement Metrics
- Net Income per Share
- -1.47
- Income Quality
- 0.81
- ROE
- -0.54
- Return On Assets
- -0.48
- Return On Capital Employed
- -0.5
- Net Income per EBT
- 1
- EBT Per Ebit
- 1.01
- Ebit per Revenue
- -6501.95
- Effective Tax Rate
- -0.01
Margins
- Sales, General, & Administrative to Revenue
- 786.27
- Research & Developement to Revenue
- 2279.69
- Stock Based Compensation to Revenue
- 651.98
- Gross Profit Margin
- -1437.6
- Operating Profit Margin
- -6501.95
- Pretax Profit Margin
- -6591.37
- Net Profit Margin
- -6591.37
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -1.2
- Free CashFlow per Share
- -1.2
- Capex to Operating CashFlow
- -0
- Capex to Revenue
- 2.34
- Capex to Depreciation
- 0.01
- Return on Invested Capital
- -0.44
- Return on Tangible Assets
- -0.43
- Days Sales Outstanding
- 8488.37
- Days Payables Outstanding
- 72.16
- Days of Inventory on Hand
- 0
- Receivables Turnover
- 0.04
- Payables Turnover
- 5.06
- Inventory Turnover
- 0
- Capex per Share
- 0
Balance Sheet
- Cash per Share
- 2,34
- Book Value per Share
- 2,71
- Tangible Book Value per Share
- 2.71
- Shareholders Equity per Share
- 2.71
- Interest Debt per Share
- 0.5
- Debt to Equity
- 0.18
- Debt to Assets
- 0.15
- Net Debt to EBITDA
- 0.3
- Current Ratio
- 12.25
- Tangible Asset Value
- 0,52 Bil.
- Net Current Asset Value
- 0,33 Bil.
- Invested Capital
- 570284000
- Working Capital
- 0,42 Bil.
- Intangibles to Total Assets
- 0
- Average Receivables
- 0,00 Bil.
- Average Payables
- 0,01 Bil.
- Average Inventory
- 0
- Debt to Market Cap
- 0.16
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Allogene Therapeutics, Inc. Profile
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
- CEO
- Dr. David D. Chang M.D., Ph.D.
- Employee
- 232
- Address
-
210 East Grand Avenue
South San Francisco, 94080
Allogene Therapeutics, Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Ms. Christine Cassiano Executive Vice President, Chief Corporate Affairs & Brand Strategy Officer |
70 |
| 2 |
Dr. Zachary J. Roberts M.D., Ph.D. Executive Vice President of Research & Development and Chief Medical Officer |
70 |
| 3 |
Ms. Annie Yoshiyama Senior Vice President, Corporate Controller & Principal Accounting Officer |
70 |
| 4 |
Dr. Arie S. Belldegrun F.A.C.S., M.D. Co-Founder & Executive Chairman |
70 |
| 5 |
Mr. Geoffrey M. Parker Executive Vice President & Chief Financial Officer |
70 |
| 6 |
Mr. Earl M. Douglas Esq. Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary |
70 |
| 7 |
Dr. David D. Chang M.D., Ph.D. Co-Founder, President, Chief Executive Officer & Director |
70 |
| 8 |
Mr. Timothy L. Moore Ph.D. Executive Vice President & Chief Technical Officer |
70 |
| 9 |
Ms. Susan R. Lundeen Chief People Officer |
70 |
| 10 |
Mr. Joshua A. Kazam Co-Founder & Director |
70 |
Allogene Therapeutics, Inc. Competitors
